ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Yigongsan decoction ameliorates anemia of chronic disease by attenuating mothers against decapentaplegic homolog-signal transducer and activator of transcription 3 interaction to regulate iron homeostasis.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveTo investigate how Yigongsan decoction (YGS) regulates iron metabolism in anemia of chronic disease (ACD) by modulating the hepcidin-ferroportin axis, with particular focus on crosstalk between the mothers against decapentaplegic homolog (SMAD) and signal transducer and activator of transcription 3 (STAT3) signaling pathways.
methods
resultsLPS-treated mice, YGS significantly decreased splenic iron content (
conclusionOur results suggest that YGS may alleviate ACD by attenuating the interaction between the SMAD and STAT3 pathways, which appears to lead to reduced STAT3 phosphorylation and hepcidin expression, thereby re-establishing iron homeostasis. This identifies YGS as a potential therapeutic agent targeting inflammation-induced iron dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.